• 首页期刊简介编委会刊物订阅专栏专刊电子刊广告合作联系我们English
引用本文:满红霞,肖培云,杨永寿,那凯歌,谭巧云.特发性肺纤维化的发病机制及药物治疗研究进展[J].中国现代应用药学,2015,32(8):1024-1028.
MAN Hongxia,XIAO Peiyun,YANG Yongshou,NA Kaige,TAN Qiaoyun.Pathogenesis of Idiopathic Pulmonary Fibrosis and Its Advances in Cytokine Treatment[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(8):1024-1028.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2343次   下载 2745 本文二维码信息
码上扫一扫!
分享到: 微信 更多
特发性肺纤维化的发病机制及药物治疗研究进展
满红霞1, 肖培云1, 杨永寿2, 那凯歌1, 谭巧云1
1.大理大学药学与化学学院,云南 大理 671000;2.云南省昆虫生物医药研发重点实验室,云南 大理 671000
摘要:
特发性肺纤维化是一种以两肺间质纤维化伴蜂窝状改变为特征的疾病,其发病率及死亡率逐年增高,且生存期较短,愈后极差,几乎与恶性肿瘤无异。因此,特发性肺纤维化发病机制和治疗也成为国际医学界的研究热点。本文就其病发机制和药物治疗研究进展进行了综述,为今后的进一步研究提供参考。
关键词:  特发性肺纤维化  发病机制  细胞因子  药物治疗
DOI:
分类号:
基金项目:国家自然科学基金项目(81360634、81060329);云南省教育厅科学研究基金项目(2011Z053);云南省科技计划项目(2015FA025)
Pathogenesis of Idiopathic Pulmonary Fibrosis and Its Advances in Cytokine Treatment
MAN Hongxia1, XIAO Peiyun1, YANG Yongshou2, NA Kaige1, TAN Qiaoyun1
1.College of Pharmacy and Chemistry, Dali University, Dali 671000, China;2.Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali 671000, China
Abstract:
Idiopathic pulmonary fibrosis is a kind of two pulmonary fibrosis disease characterized with honeycomb change, its incidence and mortality rate increased year by year, and lifetime is short, the poor prognosis is almost the same with malignant tumor. Therefore, pathogenesis and treatment of idiopathic pulmonary fibrosis has become the focus in the international medical community. The paper reviewed the disease mechanism and drug treatment research progress, to provide a reference for the further research.
Key words:  idiopathic pulmonary fibrosis  pathogenesis  cytokines  clinical medication
扫一扫关注本刊微信